Cardiovascular disease is more common in patients with chronic kidney disease (CKD), and
traditional risk factors do not adequately predict those at risk for cardiovascular (CV) events. …

The contribution of organic anion transporter OAT2 (SLC22A7) to the renal tubular secretion
of creatinine and its exact localization in the kidney are reportedly controversial. In the …

Background The gastrointestinal (GI) microbiome is recognized for potential clinical relevance
in inflammatory bowel disease (IBD). Data suggest that there is a disease-dependent loss …

Trimethylamine-N-oxide (TMAO) is a recently identified predictor of cardiovascular and
chronic kidney disease. TMAO is primarily generated through gut-microbiome mediated …

Gamma-hydroxybutyrate (GHB) is a short-chain fatty acid present endogenously in the brain
and used therapeutically for the treatment of narcolepsy, as sodium oxybate, and for alcohol …

Abemaciclib, a selective inhibitor of cyclin‐dependent kinases 4 and 6, is metabolized mainly
by cytochrome P450 (CYP)3A4. Clinical studies were performed to assess the impact of …

γ-Hydroxybutyric acid (GHB) is an endogenous neurotransmitter that is abused because of
its sedative/hypnotic and euphoric effects. The objectives of this study were to evaluate the …

Organic cation transporter 1 (OCT1) plays a role in hepatic uptake of drugs, affecting in vivo
exposure, distinguished primarily through pharmacogenetics of the SLC22A1 gene. The role …

Overdose of γ-hydroxybutyrate (GHB) frequently causes respiratory depression, occasionally
resulting in death; however, little is known about the dose-response relationship or effects …

Drug–drug interactions (DDIs) involving hepatic organic anion transporting polypeptides
1B1/1B3 (OATP1B) can be substantial, however, challenges remain for predicting interaction …